Product

EP1 (Investigational)

Name: EP1 (Investigational)
Brand: Better Cann Pharmaceutical Ltd.

InvestigationalPediatric

EP1 is an investigational, standardized, plant-derived cannabinoid formulation associated with the company’s clinical research in treatment-resistant pediatric epilepsy.

EP1 is presented here for scientific and corporate information only. It is described using approved content and is not represented as an approved medicine.

Product information

Therapeutic area: Treatment-Resistant Epilepsy
Formulation type: Standardized plant-derived cannabinoid formulation
Source genetics: Proprietary biological source genetics
Active-compound profile: Standardized active-compound profile (details available to healthcare professionals on request).
Clinical evidence: Associated with peer-reviewed, multi-center human clinical research in treatment-resistant pediatric epilepsy (Tzadok et al., Seizure 2016), in which 89% of a 74-patient cohort reported reduced seizure frequency.
Regulatory status: Investigational — not represented as an approved medicine. Regulatory details pending verification.
Availability: Availability by country pending verification.
Access level: Healthcare professionals

Medical Information Request Partnership Inquiry

Better Cann Pharmaceutical Scientific AffairsLast medically reviewed: 1 July 2026Next review: 1 July 2027

Building the Next Generation of Plant-Derived Therapeutics

Partner With Better Cann Pharmaceutical